{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:39Z","timestamp":1791908199524,"version":"4.3.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pasireotide long-acting release (PasiLAR), a somatostatin multireceptor ligand, is effective in achieving biochemical control but can increase the risk of hyperglycemia in acromegaly. However, the impact of PasiLAR on lipid and glucose metabolism in patients with acromegaly has not been systematically studied.\u00a0This systematic review aimed at synthesizing evidence on PasiLAR effects (as monotherapy or combination therapy with pegvisomant) on lipid and glucose metabolism in patients with acromegaly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MEDLINE, Embase, Cochrane Library, and Web of Science were searched for studies published between 2000 and 2024. Prospective and retrospective studies reporting metabolic outcomes before and under PasiLAR treatment for a minimum follow-up of 6 months. Two reviewers screened eligible publications (3441), extracted outcomes, and assessed risk of bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nineteen studies (896 patients) were included in the meta-analysis. PasiLAR was associated with increased fasting plasma glucose (FPG) (mean difference [MD] 23.4\u00a0mg\/dL, 95% confidence interval [95%CI] 18.8\u201328.1]) and glycated hemoglobin (HbA\n                      <jats:sub>1c<\/jats:sub>\n                      ) (MD 0.5%, 95%CI 0.4\u20130.7). A higher frequency of diabetes mellitus (DM) was observed after treatment (odds ratio 3.7, 95%CI 2.9\u20134.7). No significant changes in triglycerides, total cholesterol, or low-density lipoprotein cholesterol (LDL-C), and a modest but significant increase in high-density lipoprotein cholesterol (HDL-C) were recorded (MD 6.2\u00a0mg\/dL, 95%CI 1.4\u201310.9]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large meta-analysis, PasiLAR was associated with increased HDL-C, FPG, HbA1c, and frequency of DM in patients with acromegaly. There was no effect on triglycerides, total cholesterol, and LDL-C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42024544686.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-025-02642-0","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T03:23:31Z","timestamp":1751858611000},"page":"2799-2812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0942-0496","authenticated-orcid":false,"given":"Flavia","family":"Costanza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4680-3058","authenticated-orcid":false,"given":"Christian","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-2392","authenticated-orcid":false,"given":"Sabrina","family":"Chiloiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0040-7930","authenticated-orcid":false,"given":"Eva","family":"Hessman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1660-1973","authenticated-orcid":false,"given":"Dimitrios","family":"Chantzichristos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0570-6865","authenticated-orcid":false,"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-2448","authenticated-orcid":false,"given":"Emanuele","family":"Bobbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-2071","authenticated-orcid":false,"given":"Daniela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"2642_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41574-024-00993-x","volume":"20","author":"D Esposito","year":"2024","unstructured":"Esposito D, Boguszewski CL, Colao A et al (2024) Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management. Nat Rev Endocrinol 20:541\u2013552. https:\/\/doi.org\/10.1038\/s41574-024-00993-x","journal-title":"Nat Rev Endocrinol"},{"key":"2642_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1210\/er.2002-0022","volume":"25","author":"A Colao","year":"2004","unstructured":"Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102\u2013152. https:\/\/doi.org\/10.1210\/er.2002-0022","journal-title":"Endocr Rev"},{"key":"2642_CR3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10:804\u2013826. https:\/\/doi.org\/10.1016\/S2213-8587(22)00244-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2642_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 40:268\u2013332. https:\/\/doi.org\/10.1210\/er.2018-00115","journal-title":"Endocr Rev"},{"key":"2642_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1210\/jc.2007-1191","volume":"93","author":"OM Dekkers","year":"2008","unstructured":"Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93:61\u201367. https:\/\/doi.org\/10.1210\/jc.2007-1191","journal-title":"J Clin Endocrinol Metab"},{"key":"2642_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","volume":"27","author":"S Frara","year":"2016","unstructured":"Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab 27:470\u2013483. https:\/\/doi.org\/10.1016\/j.tem.2016.04.014","journal-title":"Trends Endocrinol Metab"},{"key":"2642_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11102-017-0797-7","volume":"20","author":"R Pivonello","year":"2017","unstructured":"Pivonello R, Auriemma RS, Grasso LFS et al (2017) Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 20:46\u201362. https:\/\/doi.org\/10.1007\/s11102-017-0797-7","journal-title":"Pituitary"},{"key":"2642_CR8","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1210\/clinem\/dgac400","volume":"107","author":"D Esposito","year":"2022","unstructured":"Esposito D, Olsson DS, Franz\u00e9n S et al (2022) Effect of diabetes on morbidity and mortality in patients with acromegaly. J Clin Endocrinol Metab 107:2483\u20132492. https:\/\/doi.org\/10.1210\/clinem\/dgac400","journal-title":"J Clin Endocrinol Metab"},{"key":"2642_CR9","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A et al (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab 105:e937\u2013946. https:\/\/doi.org\/10.1210\/clinem\/dgz096","journal-title":"J Clin Endocrinol Metab"},{"key":"2642_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12020-013-9904-3","volume":"44","author":"VE Chaves","year":"2013","unstructured":"Chaves VE, J\u00fanior FM, Bertolini GL (2013) The metabolic effects of growth hormone in adipose tissue. Endocrine 44:293\u2013302. https:\/\/doi.org\/10.1007\/s12020-013-9904-3","journal-title":"Endocrine"},{"key":"2642_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000486001","volume":"49","author":"M Mercado","year":"2018","unstructured":"Mercado M, Ram\u00edrez-Renter\u00eda C (2018) Metabolic complications of acromegaly. Front Horm Res 49:20\u201328. https:\/\/doi.org\/10.1159\/000486001","journal-title":"Front Horm Res"},{"key":"2642_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11102-011-0365-5","volume":"15","author":"C Giordano","year":"2012","unstructured":"Giordano C, Ciresi A, Amato MC et al (2012) Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 15:539\u2013551. https:\/\/doi.org\/10.1007\/s11102-011-0365-5","journal-title":"Pituitary"},{"key":"2642_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27:7\u201322. https:\/\/doi.org\/10.1007\/s11102-023-01360-1","journal-title":"Pituitary"},{"key":"2642_CR14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P et al (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14:552\u2013561. https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat Rev Endocrinol"},{"key":"2642_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU et al (2021) A pituitary society update to acromegaly management guidelines. Pituitary 24:1\u201313. https:\/\/doi.org\/10.1007\/s11102-020-01091-7","journal-title":"Pituitary"},{"key":"2642_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrendo.2011.42","volume":"7","author":"M Sherlock","year":"2011","unstructured":"Sherlock M, Woods C, Sheppard MC (2011) Medical therapy in acromegaly. Nat Rev Endocrinol 7:291\u2013300. https:\/\/doi.org\/10.1038\/nrendo.2011.42","journal-title":"Nat Rev Endocrinol"},{"key":"2642_CR17","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2018-02281","volume":"104","author":"T Feola","year":"2019","unstructured":"Feola T, Cozzolino A, Simonelli I et al (2019) Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab 104:2892\u20132902. https:\/\/doi.org\/10.1210\/jc.2018-02281","journal-title":"J Clin Endocrinol Metab"},{"key":"2642_CR18","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1210\/jc.2008-2332","volume":"94","author":"G Mazziotti","year":"2009","unstructured":"Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94:1500\u20131508. https:\/\/doi.org\/10.1210\/jc.2008-2332","journal-title":"J Clin Endocrinol Metab"},{"key":"2642_CR19","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1210\/jc.2017-02566","volume":"103","author":"A Cozzolino","year":"2018","unstructured":"Cozzolino A, Feola T, Simonelli I et al (2018) Somatostatin analogs and glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab 103:2089\u20132099. https:\/\/doi.org\/10.1210\/jc.2017-02566","journal-title":"J Clin Endocrinol Metab"},{"key":"2642_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0021-9150(99)00426-8","volume":"151","author":"M Arosio","year":"2000","unstructured":"Arosio M, Sartore G, Rossi CM, Casati G, Faglia G, Manzato E (2000) LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Atherosclerosis 151:551\u2013557. https:\/\/doi.org\/10.1016\/S0021-9150(99)00426-8","journal-title":"Atherosclerosis"},{"key":"2642_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1530\/eje.0.1460303","volume":"146","author":"A Colao","year":"2002","unstructured":"Colao A, Marzullo P, Lombardi G et al (2002) Effect of a six-month treatment with Lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 146:303\u2013309. https:\/\/doi.org\/10.1530\/eje.0.1460303","journal-title":"Eur J Endocrinol"},{"key":"2642_CR22","volume-title":"Endotext [Internet]","author":"KR Feingold","year":"2023","unstructured":"Feingold KR (2000) The effect of endocrine disorders on lipids and lipoproteins. [Updated 2023 Apr 6]. In: Feingold KR, Ahmed SF, Anawalt B et al (eds) Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK409608\/"},{"key":"2642_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1046\/j.1365-2265.2002.01460.x","volume":"56","author":"C Parkinson","year":"2002","unstructured":"Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ (2002) Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol (Oxf) 56:303\u2013311. https:\/\/doi.org\/10.1046\/j.1365-2265.2002.01460.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2642_CR24","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1210\/jcem.87.4.8364","volume":"87","author":"G Sesmilo","year":"2002","unstructured":"Sesmilo G, Fairfield WP, Katznelson L et al (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist Pegvisomant. J Clin Endocrinol Metab 87:1692\u20131699. https:\/\/doi.org\/10.1210\/jcem.87.4.8364","journal-title":"J Clin Endocrinol Metab"},{"key":"2642_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/DDDT.S77999","volume":"10","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Cuevas-Ramos D (2016) Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther 10:227\u2013239. https:\/\/doi.org\/10.2147\/DDDT.S77999","journal-title":"Drug Des Devel Ther"},{"key":"2642_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11102-018-0926-y","volume":"22","author":"F Gatto","year":"2019","unstructured":"Gatto F, Arvigo M, Amar\u00f9 J et al (2019) Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. Pituitary 22:89\u201399. https:\/\/doi.org\/10.1007\/s11102-018-0926-y","journal-title":"Pituitary"},{"key":"2642_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12020-022-03158-w","volume":"78","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro S, Costa D, Lauretta R et al (2022) Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly. Endocrine 78:343\u2013353. https:\/\/doi.org\/10.1007\/s12020-022-03158-w","journal-title":"Endocrine"},{"key":"2642_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11154-024-09928-3","volume":"26","author":"B Biagetti","year":"2025","unstructured":"Biagetti B, Araujo-Castro M, Tebe C, Marazuela M, Puig-Domingo M (2025) Real-world evidence of effectiveness and safety of Pasireotide in the treatment of acromegaly: a systematic review and meta-analysis. Rev Endocr Metab Disord 26:97\u2013111. https:\/\/doi.org\/10.1007\/s11154-024-09928-3","journal-title":"Rev Endocr Metab Disord"},{"key":"2642_CR29","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1517\/13543784.2014.942728","volume":"23","author":"A Giustina","year":"2014","unstructured":"Giustina A, Mazziotti G, Maffezzoni F, Amoroso V, Berruti A (2014) Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opin Investig Drugs 23:1619\u20131635. https:\/\/doi.org\/10.1517\/13543784.2014.942728","journal-title":"Expert Opin Investig Drugs"},{"key":"2642_CR30","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1210\/jc.2006-1578","volume":"92","author":"V Singh","year":"2007","unstructured":"Singh V, Brendel MD, Zacharias S et al (2007) Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic Islets. J Clin Endocrinol Metab 92:673\u2013680. https:\/\/doi.org\/10.1210\/jc.2006-1578","journal-title":"J Clin Endocrinol Metab"},{"key":"2642_CR31","doi-asserted-by":"publisher","first-page":"E1010","DOI":"10.1152\/ajpendo.2000.278.6.E1010","volume":"278","author":"L Hansen","year":"2000","unstructured":"Hansen L, Hartmann B, Bisgaard T, Mineo H, J\u00f8rgensen PN, Holst JJ (2000) Somatostatin restrains the secretion of glucagon-like peptide-1 and\u2013\u20092 from isolated perfused Porcine ileum. Am J Physiol Endocrinol Metab 278:E1010\u20131018. https:\/\/doi.org\/10.1152\/ajpendo.2000.278.6.E1010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2642_CR32","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"371","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 371:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"2642_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C (2016) PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 75:40\u201346. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.01.021","journal-title":"J Clin Epidemiol"},{"key":"2642_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","volume":"10","author":"ML Rethlefsen","year":"2021","unstructured":"Rethlefsen ML, Kirtley S, Waffenschmidt S et al (2021) PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev 10:39. https:\/\/doi.org\/10.1186\/s13643-020-01542-z","journal-title":"Syst Rev"},{"key":"2642_CR35","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186","journal-title":"Stat Med"},{"key":"2642_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","volume":"316","author":"M Egger","year":"1998","unstructured":"Egger M, Smith GD (1998) Meta-analysis bias in location and selection of studies. BMJ 316:61\u201366. https:\/\/doi.org\/10.1136\/bmj.316.7124.61","journal-title":"BMJ"},{"issue":"4","key":"2642_CR37","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/cen.14946","volume":"99","author":"S Ruiz","year":"2023","unstructured":"Ruiz S, Gil J, Biagetti B et al (2023) Magnetic resonance imaging as a predictor of therapeutic response to Pasireotide in acromegaly. Clin Endocrinol (Oxf) 99(4):378\u2013385. https:\/\/doi.org\/10.1111\/cen.14946","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2642_CR38","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s12020-021-02711-3","volume":"73","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Visconti F et al (2021) Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. Endocrine 73:658\u2013666. https:\/\/doi.org\/10.1007\/s12020-021-02711-3","journal-title":"Endocrine"},{"key":"2642_CR39","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/jc.2017-02017","volume":"103","author":"A Muhammad","year":"2018","unstructured":"Muhammad A, van der Lely AJ, Delhanty PJD et al (2018) Efficacy and safety of switching to Pasireotide in patients with acromegaly controlled with Pegvisomant and first-generation somatostatin analogues (PAPE Study). J Clin Endocrinol Metab 103:586\u2013595. https:\/\/doi.org\/10.1210\/jc.2017-02017","journal-title":"J Clin Endocrinol Metab"},{"key":"2642_CR40","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T et al (2014) Pasireotide versus continued treatment with octreotide or Lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2:875\u2013884. https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2642_CR41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s12020-016-1182-4","volume":"55","author":"M Fleseriu","year":"2017","unstructured":"Fleseriu M, Rusch E, Geer EB (2017) Safety and tolerability of Pasireotide long-acting release in acromegaly\u2014results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine 55:247\u2013255. https:\/\/doi.org\/10.1007\/s12020-016-1182-4","journal-title":"Endocrine"},{"key":"2642_CR42","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1507\/endocrj.EJ16-0624","volume":"64","author":"S Tahara","year":"2017","unstructured":"Tahara S, Murakami M, Kaneko T, Shimatsu A, ACCESS Study Investigators (2017) Efficacy and safety of long-acting Pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocr J 64:735\u2013747. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0624","journal-title":"Endocr J"},{"key":"2642_CR43","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","volume":"62","author":"I Shimon","year":"2018","unstructured":"Shimon I, Adnan Z, Gorshtein A et al (2018) Efficacy and safety of long-acting Pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine 62:448\u2013455. https:\/\/doi.org\/10.1007\/s12020-018-1690-5","journal-title":"Endocrine"},{"key":"2642_CR44","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3389\/fendo.2019.00931","volume":"10","author":"M Gadelha","year":"2020","unstructured":"Gadelha M, Bex M, Colao A et al (2020) Evaluation of the efficacy and safety of switching to Pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs. Front Endocrinol (Lausanne) 10:931. https:\/\/doi.org\/10.3389\/fendo.2019.00931","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2642_CR45","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1530\/EC-19-0332","volume":"8","author":"H Lasolle","year":"2019","unstructured":"Lasolle H, Ferriere A, Vasiljevic A, Eimer S, Nunes ML, Tabarin A (2019) Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study. Endocr Connect 8:1383\u20131394. https:\/\/doi.org\/10.1530\/EC-19-0332","journal-title":"Endocr Connect"},{"key":"2642_CR46","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.4158\/EP-2020-0171","volume":"26","author":"H Masri-Iraqi","year":"2020","unstructured":"Masri-Iraqi H, Akirov A, Shimon I (2020) Medical treatment landscape for active acromegaly in a pituitary center in Israel. Endocr Pract 26:1298\u20131303. https:\/\/doi.org\/10.4158\/EP-2020-0171","journal-title":"Endocr Pract"},{"key":"2642_CR47","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","volume":"24","author":"SL Samson","year":"2021","unstructured":"Samson SL, Gu F, Feldt-Rasmussen U et al (2021) Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study. Pituitary 24:887\u2013903. https:\/\/doi.org\/10.1007\/s11102-021-01161-4","journal-title":"Pituitary"},{"key":"2642_CR48","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","volume":"18","author":"M Sheppard","year":"2015","unstructured":"Sheppard M, Bronstein MD, Freda P et al (2015) Pasireotide LAR maintains Inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study. Pituitary 18:385\u2013394. https:\/\/doi.org\/10.1007\/s11102-014-0585-6","journal-title":"Pituitary"},{"key":"2642_CR49","doi-asserted-by":"publisher","first-page":"633944","DOI":"10.3389\/fendo.2021.633944","volume":"12","author":"P Witek","year":"2021","unstructured":"Witek P, Bolanowski M, Szamotulska K, Wojciechowska-Lu\u017aniak A, Jawiarczyk-Przyby\u0142owska A, Ka\u0142u\u017cny M (2021) The effect of 6 months\u2019 treatment with Pasireotide Lar on glucose metabolism in patients with resistant acromegaly in real-world clinical settings. Front Endocrinol (Lausanne) 12:633944. https:\/\/doi.org\/10.3389\/fendo.2021.633944","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2642_CR50","doi-asserted-by":"publisher","first-page":"e220296","DOI":"10.1530\/EC-22-0296","volume":"11","author":"P Wolf","year":"2022","unstructured":"Wolf P, Dormoy A, Maione L et al (2022) Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with Pasireotide LAR. Endocr Connect 11:e220296. https:\/\/doi.org\/10.1530\/EC-22-0296","journal-title":"Endocr Connect"},{"key":"2642_CR51","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11102-021-01185-w","volume":"25","author":"M Stelmachowska-Bana\u015b","year":"2022","unstructured":"Stelmachowska-Bana\u015b M, Czajka-Oraniec I, Tomasik A, Zgliczy\u0144ski W (2022) Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation. Pituitary 25:180\u2013190. https:\/\/doi.org\/10.1007\/s11102-021-01185-w","journal-title":"Pituitary"},{"key":"2642_CR52","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s40618-023-02186-1","volume":"47","author":"G Corica","year":"2023","unstructured":"Corica G, Pirchio R, Milioto A et al (2023) Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs. J Endocrinol Invest 47:683\u2013697. https:\/\/doi.org\/10.1007\/s40618-023-02186-1","journal-title":"J Endocrinol Invest"},{"key":"2642_CR53","doi-asserted-by":"publisher","first-page":"1344728","DOI":"10.3389\/fendo.2024.1344728","volume":"15","author":"V Favero","year":"2024","unstructured":"Favero V, Zampetti B, Carioni EI et al (2024) Efficacy of Pasireotide LAR for acromegaly: a prolonged real-world monocentric study. Front Endocrinol (Lausanne) 15:1344728. https:\/\/doi.org\/10.3389\/fendo.2024.1344728","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2642_CR54","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s40618-023-02299-7","volume":"47","author":"R Pirchio","year":"2024","unstructured":"Pirchio R, Auriemma RS, Vergura A, Pivonello R, Colao A (2024) Long-term Pasireotide therapy in acromegaly: extensive real-life experience of a referral center. J Endocrinol Invest 47:1887\u20131901. https:\/\/doi.org\/10.1007\/s40618-023-02299-7","journal-title":"J Endocrinol Invest"},{"key":"2642_CR55","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s40618-023-02275-1","volume":"47","author":"C Urbani","year":"2024","unstructured":"Urbani C, Dassie F, Zampetti B et al (2024) Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up. J Endocrinol Invest 47:1733\u20131741. https:\/\/doi.org\/10.1007\/s40618-023-02275-1","journal-title":"J Endocrinol Invest"},{"key":"2642_CR56","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11102-013-0478-0","volume":"17","author":"S Petersenn","year":"2014","unstructured":"Petersenn S, Farrall AJ, Block C et al (2014) Long-term efficacy and safety of subcutaneous Pasireotide in acromegaly: results from an open-ended, multicenter, phase II extension study. Pituitary 17:132\u2013140. https:\/\/doi.org\/10.1007\/s11102-013-0478-0","journal-title":"Pituitary"},{"key":"2642_CR57","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12902-016-0096-8","volume":"16","author":"MD Bronstein","year":"2016","unstructured":"Bronstein MD, Fleseriu M, Neggers S et al (2016) Switching patients with acromegaly from octreotide to Pasireotide improves biochemical control: crossover extension to a randomized, double-blind, phase III study. BMC Endocr Disord 16:16. https:\/\/doi.org\/10.1186\/s12902-016-0096-8","journal-title":"BMC Endocr Disord"},{"key":"2642_CR58","doi-asserted-by":"publisher","first-page":"e1571","DOI":"10.1210\/clinem\/dgad378","volume":"108","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Marques NV, Fialho C et al (2023) Long-term efficacy and safety of Pasireotide in patients with acromegaly: 14 years of single-center real-world experience. J Clin Endocrinol Metab 108:e1571\u20131579. https:\/\/doi.org\/10.1210\/clinem\/dgad378","journal-title":"J Clin Endocrinol Metab"},{"key":"2642_CR59","doi-asserted-by":"publisher","first-page":"e240043","DOI":"10.1530\/ERC-24-0043","volume":"31","author":"M Araujo-Castro","year":"2024","unstructured":"Araujo-Castro M, Biagetti B, Men\u00e9ndez Torre E et al (2024) Pegvisomant and Pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. Endocr Relat Cancer 31:e240043. https:\/\/doi.org\/10.1530\/ERC-24-0043","journal-title":"Endocr Relat Cancer"},{"key":"2642_CR60","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P et al (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99:791\u2013799. https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"key":"2642_CR61","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jfma.2016.02.003","volume":"115","author":"JS Chang","year":"2016","unstructured":"Chang JS, Tseng HM, Chang TC (2016) Serial follow-up of presurgical treatment using Pasireotide long-acting release with or without octreotide long-acting release for Na\u00efve active acromegaly. J Formos Med Assoc 115:475\u2013480. https:\/\/doi.org\/10.1016\/j.jfma.2016.02.003","journal-title":"J Formos Med Assoc"},{"key":"2642_CR62","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","volume":"53","author":"HA Schmid","year":"2016","unstructured":"Schmid HA, Brue T, Colao A et al (2016) Effect of Pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 53:210\u2013219. https:\/\/doi.org\/10.1007\/s12020-016-0895-8","journal-title":"Endocrine"},{"key":"2642_CR63","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/EJE-18-0353","volume":"179","author":"A Muhammad","year":"2018","unstructured":"Muhammad A, Coopmans EC, Delhanty PJD et al (2018) Efficacy and safety of switching to Pasireotide in acromegaly patients controlled with Pegvisomant and somatostatin analogues: PAPE extension study. Eur J Endocrinol 179:269\u2013277. https:\/\/doi.org\/10.1530\/EJE-18-0353","journal-title":"Eur J Endocrinol"},{"key":"2642_CR64","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","volume":"182","author":"A Colao","year":"2020","unstructured":"Colao A, Bronstein MD, Brue T et al (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the phase III PAOLA study. Eur J Endocrinol 182:583. https:\/\/doi.org\/10.1530\/EJE-19-0762","journal-title":"Eur J Endocrinol"},{"key":"2642_CR65","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12020-021-02782-2","volume":"74","author":"A Akirov","year":"2021","unstructured":"Akirov A, Gorshtein A, Dotan I et al (2021) Long-term safety and efficacy of long-acting Pasireotide in acromegaly. Endocrine 74:396\u2013403. https:\/\/doi.org\/10.1007\/s12020-021-02782-2","journal-title":"Endocrine"},{"key":"2642_CR66","doi-asserted-by":"publisher","first-page":"1250822","DOI":"10.3389\/fendo.2024.1250822","volume":"15","author":"U Feldt-Rasmussen","year":"2024","unstructured":"Feldt-Rasmussen U, Bolanowski M, Zhang SL et al (2024) Predictive factors and the management of hyperglycemia in patients with acromegaly and cushing\u2019s disease receiving Pasireotide treatment: post hoc analyses from the SOM230B2219 study. Front Endocrinol (Lausanne) 15:1250822. https:\/\/doi.org\/10.3389\/fendo.2024.1250822","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2642_CR67","doi-asserted-by":"publisher","first-page":"e230155","DOI":"10.1530\/EC-23-0155","volume":"12","author":"NV Marques","year":"2023","unstructured":"Marques NV, Wildemberg LEA, Gadelha MR (2023) Long-term, real-world experience of Pasireotide dose reduction in patients with acromegaly. Endocr Connect 12:e230155. https:\/\/doi.org\/10.1530\/EC-23-0155","journal-title":"Endocr Connect"},{"key":"2642_CR68","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1161\/01.atv.8.6.737","volume":"8","author":"PW Wilson","year":"1988","unstructured":"Wilson PW, Abbott RD, Castelli WP (1988) High density lipoprotein cholesterol and mortality. Framingham Heart Study Arterioscler 8:737\u2013741. https:\/\/doi.org\/10.1161\/01.atv.8.6.737","journal-title":"Framingham Heart Study Arterioscler"},{"issue":"39","key":"2642_CR69","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"44","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J 44(39):3925\u20133946. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361","journal-title":"Eur Heart J"},{"issue":"7","key":"2642_CR70","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","volume":"7","author":"F Duarte Lau","year":"2022","unstructured":"Duarte Lau F, Giugliano RP (2022) Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol 7(7):760\u2013769. https:\/\/doi.org\/10.1001\/jamacardio.2022.0987","journal-title":"JAMA Cardiol"},{"key":"2642_CR71","doi-asserted-by":"publisher","first-page":"123576","DOI":"10.1016\/j.lfs.2025.123576","volume":"1370","author":"K Sayehmiri","year":"2025","unstructured":"Sayehmiri K, Shohani M, Qavam S et al (2025) Comparing the effectiveness of Rosuvastatin and Atorvastatin on changes in LDL, TG and HDL: A systematic review and meta-analysis. Life Sci 1370:123576. https:\/\/doi.org\/10.1016\/j.lfs.2025.123576","journal-title":"Life Sci"},{"key":"2642_CR72","doi-asserted-by":"publisher","first-page":"3987065","DOI":"10.1155\/2020\/3987065","volume":"23","author":"X Zhang","year":"2020","unstructured":"Zhang X, Xing L, Jia X et al (2020) Comparative Lipid-Lowering\/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials. Cardiovasc Ther 23:3987065. https:\/\/doi.org\/10.1155\/2020\/3987065","journal-title":"Cardiovasc Ther"},{"issue":"2","key":"2642_CR73","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4103\/0253-7613.93864","volume":"44","author":"MA Jose","year":"2012","unstructured":"Jose MA, Anandkumar S, Narmadha MP, Sandeep M (2012) A comparative effect of Atorvastatin with other Statins in patients of hyperlipidemia. Indian J Pharmacol 44(2):261\u2013263. https:\/\/doi.org\/10.4103\/0253-7613.93864","journal-title":"Indian J Pharmacol"},{"key":"2642_CR74","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11102-024-01461-5","volume":"27","author":"T Aliyeva","year":"2024","unstructured":"Aliyeva T, Muniz J, Soares GM, Firdausa S, Mirza L (2024) Efficacy and safety of Pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis. Pituitary 27:468\u2013479. https:\/\/doi.org\/10.1007\/s11102-024-01461-5","journal-title":"Pituitary"},{"key":"2642_CR75","doi-asserted-by":"publisher","first-page":"1348990","DOI":"10.3389\/fendo.2024.1348990","volume":"15","author":"S St\u00f6rmann","year":"2024","unstructured":"St\u00f6rmann S, Meyh\u00f6fer SM, Groener JB et al (2024) Management of pasireotide-induced hyperglycemia in patients with acromegaly: an experts\u2019 consensus statement. Front Endocrinol (Lausanne) 15:1348990. https:\/\/doi.org\/10.3389\/fendo.2024.1348990","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2642_CR76","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1530\/EC-20-0361","volume":"9","author":"MR Gadelha","year":"2020","unstructured":"Gadelha MR, Gu F, Bronstein MD et al (2020) Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect 9:1178\u20131190. https:\/\/doi.org\/10.1530\/EC-20-0361","journal-title":"Endocr Connect"},{"key":"2642_CR77","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s12020-023-03325-7","volume":"80","author":"A Giampietro","year":"2023","unstructured":"Giampietro A, Menotti S, Chiloiro S, Pontecorvi A, De Marinis L, Bianchi A (2023) De-escalation treatment with Pasireotide for acromegaly: a long-term experience. Endocrine 80:505\u2013510. https:\/\/doi.org\/10.1007\/s12020-023-03325-7","journal-title":"Endocrine"},{"key":"2642_CR78","doi-asserted-by":"publisher","first-page":"84","DOI":"10.14310\/horm.2002.1722","volume":"16","author":"I Shimon","year":"2017","unstructured":"Shimon I, Saeger W, Wildemberg LE, Gadelha MR (2017) Somatotropinomas inadequately controlled with octreotide May over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control. Horm (Athens) 16:84\u201391. https:\/\/doi.org\/10.14310\/horm.2002.1722","journal-title":"Horm (Athens)"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02642-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02642-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02642-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T04:51:48Z","timestamp":1763787108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02642-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":78,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2642"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02642-0","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Sabrina Chiloiro has received research grants for their institution from Ipsen, Pfizer, and Recordati, as well aslecture fees from Recordati. Maria Fleseriu has received research support to the University as principal investigator from Crinetics and has received consulting fees from Amolyt, Camurus, Crinetics, and Recordati. Daniela Esposito has received lecture fees from Ipsen, Recordati, and Pfizer AB. Daniela Esposito serves as Associate Editor for\n                      Journal of Endocrinological Investigation\n                      . Flavia Costanza, Christian Basile, Eva Hessman, Dimitrios Chantzichristos, Alfredo Pontecorvi, and Emanuele Bobbio declare no relevant disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}